CD274 and endometrial cancer: KEYNOTE-028, a multicohort phase Ib clinical study, enrolled 24 patients with PD-L1-positive advanced endometrial cancer with one patient distinguished by POLE mutation, one MSI, and the other patients undefined, all receiving pembrolizumab treatment.